Drospirenone Archives - Carey Danis & Lowe

UK Doctors Warn Patients of Yasmin & Yaz Side Effects

By | Pharmaceutical litigation, Uncategorized, Yaz/Yasmin

yaz_lawsuit_yasmin_side_effects_lawsuits_dvt_blood_clot_settlementsAn article recently published by UK news organization the Daily Mail describes the country’s increased efforts in requiring physicians to adequately warn patients of the risks of using certain kinds of oral contraceptives. The article specifically mentions the oral contraceptive drug, Yasmin, which is manufactured by Bayer, the pharmaceutical company behind Yaz.

Health officials in the UK announced their new initiative amid reports that newer types of oral contraceptives place women at two times the risk of developing blood clots.

Both Yasmin and Yaz contain a newer type of synthetic hormone, what is called a third-generation progestin. A number of these third-generation progestins have been linked to an increased risk in the development of blood clots. Drospirenone, the type of progestin present in both Yasmin and Yaz, as well as generic counterpart Ocella, is just such a progestin that has been linked through numerous studies to a higher risk of venous thromboembolism.

The personal injury and defective drug lawyers at Carey Danis & Lowe are encouraged to see health officials in the United Kingdom act on the serious threats posed by Yasmin and Yaz to patient health and safety.

Carey Danis & Lowe represents victims of Yasmin and Yaz across the United States. If you believe that you have been injured by Yasmin or Yaz, we welcome you to begin exploring your legal options and eligibility for compensation today with a Carey Danis & Lowe attorney. Our initial case evaluations are free.

Carey Danis & Lowe is available to listen to your story today. Share with us how Yasmin or Yaz has impacted your health and quality of life. Contact Carey Danis & Lowe by phone at 800.721.2519, or complete one of our confidential personal injury claim forms.

Yaz/Yasmin DVT & Pulmonary Embolism Settlements Progressing

By | Pharmaceutical litigation, Uncategorized, Yaz/Yasmin

Published July 10, 2012 by LawsuintInformation

Yaz Deep Vein Thrombosis & Pulmonary Embolism Settlements ProgressingAs a Yaz Pulmonary Embolism, Deep Vein Thrombosis Attorney I have written extensively about the risks inherent in birth control pills containing Drospirenone.

According to status report held on June 22, in the U.S. District Court for the Southern District of Illinois, Bayer has reached agreements with about 33 different law firms to resolve at least 1,444 Yaz Deep Vein Thrombosis, Stroke and Pulmonary Embolism claims.

According to Bloomberg News, as of late April, Bayer faced 11,900 lawsuits over Yaz and its sister drug Yasmin in the U.S. with about 14,000 plaintiffs. Experts predict that the company may have to pay up to $2.65 billion to settle all of the pending cases.

Bayer, the manufacturer of Yaz, Yasmin and Ocella, began settlement negotiations earlier in January, with women who claimed venous thromboembolism blood clot-related personal injuries allegedly caused by side effects of these oral contraceptive birth control pills.

Yaz Federal MDL

All federal cases have been centralized for pretrial proceedings in the U.S. District Court for the Southern District of Illinois. These lawsuits are consolidated as part of an MDL, or multidistrict litigation.

No Venous Thrombotic Bellwether Trials

According to the hearing conference minutes, the judge overseeing the MDL litigation, opined that there are not going to be any bellwether cases involving venous thrombotic injuries. The reason apparently was because the settlement process is continuing to work to resolve the remaining injury cases.

Bayer is only settling Yaz lawsuits involving a pulmonary embolism or deep vein thrombosis injury at this time. A deep vein thrombosis (DVT) is a blood clot that occurs in the deep veins of the legs or pelvis. A pulmonary embolism occurs when the leg blood clot breaks off, travels through the blood stream and becomes lodged in the lung.

Judge Extends Yaz Lawsuit Deadlines to Allow More Settlements

By | Pharmaceutical litigation, Uncategorized, Yaz/Yasmin

Published May 7, 2012 on LawsuitInformation.org

A judge overseeing the multidistrict litigation (MDL) regarding the oral contraceptive Yaz has cleared the way for more settlement negotiations to continue.

Chief Judge David R. Herndon, of the U.S. District Court for the Southern District of Illinois, moved back the deadlines for Yaz lawsuits, allowing for the drug’s maker, Bayer, and attorneys to negotiate settlements for the more than 11,000 remaining lawsuits regarding the blood clot risks associated with the drug.

This is the third time the judge has granted a deadline extension for the court cases to begin.

Already, Bayer has agreed to pay out $142 million to settle 651 cases but will not admit any fault in the drug’s connection to deadly blood clots. The settlements come out to about $218,000 per case.

The Germany-based Bayer originally faced 11,900 lawsuits in the United States alone with about 14,000 plaintiffs. Experts say the company will have to pay up to $2.65 billion to settle the remaining cases.

The problem with Yaz started from the get-go. While the birth control pill contained a generic form of estrogen like other pills on the market, it also contained a new synthetic form of progesterone called drospirenone. Studies now show that drospirenone is linked to elevated stroke and blood clot risks.

Early on, though, Yaz was sensationalized through a multi-million dollar advertising campaign that promoted the drug as hip and cool. It was promoted as a way to not only prevent unwanted pregnancies but also prevent acne, premenstrual moodiness and bloating.

With its flashy ads and catch phrases, Yaz quickly became the top selling birth control pill in the U.S. In 2010 alone, it generated $1.58 billion in sales.

By 2011, the curtain was closing on Yaz as more and more research pointed to the drug’s deadly side effects. Girls as young as age 13 were dying from Yaz-related blood clots while the drug company continually denied any wrongdoing.

It took the U.S. Food and Drug Administration (FDA) years to finally step in and acknowledge a problem with Yaz. It wasn’t until early April that federal drug regulators ordered Bayer to include tougher blood-clot warnings on the drug’s label.

The warning states that drospirenone triples the risk for deadly blood clots. Just weeks after the FDA stepped in, the first round of Yaz court settlements were announced.

The first nine test trials for Yaz MDL were at first scheduled to being in September 2011 and then January 2012. By mid January, Herndon delayed the test trials indefinitely and ordered mediation at Bayer’s request. The trials were scheduled to begin on April 30 if the mediation failed.